Symbiotec Pharmalabs shares surge 19% to a new post-listing high after 10-year deal with European protein innovator

Shares of the recently-listed Symbiotec Pharmalabs Ltd. gained nearly 20% to hit a fresh post-listing high after the company announced a decade-long take-or-pay contract development and manufacturing agreement with a European alternative protein innovator.The agreement reserves dedicated capacity f…